# colorectal cancer - gemini-3.6-flash

- Benchmark system: raw
- Repeat: 2
- Task type: PROGNOSIS
- Tissue / sample source: colorectal tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: Google Gemini / gemini-3.6-flash
- Message SHA-256: dfb8fe82357dbea353d34030380d74028b528c91505f5793c7261ee9e4376675
- Response HTTP status: 200
- Prompt tokens: 5297
- Completion tokens: 12894
- Reasoning tokens: 
- Total tokens: 18191
- API requests reported: 
- Elapsed seconds: 23.787
- Final benchmark system: raw; file rank 1/5; original repeat 2; model vendor: Google Gemini

---
### 1. Overall Biological Interpretation

The transcriptomic survival analysis in colorectal tumor tissues reveals a binary prognostic division governed by two opposing cellular programs:

1. **Protective Axis ($\text{HR} < 1$, Favorable Overall Survival):** Characterized by the co-preservation of mature **intestinal epithelial lineage differentiation**, apical enterocyte polarity (e.g., *CDX2*, *CDX1*, *MYO5B*, *LGALS4*), and **mitochondrial oxidative phosphorylation** (e.g., *NDUFA9*, *ATP23*, *ATP5G1*, *ATP5B*, *CS*, *OGDHL*). High expression of these genes reflects tumors that retain differentiated enterocyte identity and intact mitochondrial respiration, characteristic of less aggressive, lower-grade tumors (aligning functionally with Consensus Molecular Subtypes CMS2 and CMS3).

2. **Risk Axis ($\text{HR} > 1$, Unfavorable Overall Survival):** Driven by **TGF-$\beta$/Activin paracrine signaling**, **extracellular matrix (ECM) remodeling**, **epithelial-mesenchymal transition (EMT)**, and **ectonucleotidase-mediated immunosuppression**. Key drivers include ligands/receptors (*INHBB*, *ITGBL1*, *DCBLD2*), non-coding EMT regulators (*ZEB1-AS1*, *MIR31HG*), cytoskeletal remodelers (*TPM4*, *ABL2*), and ecto-enzymes (*NT5E* / CD73). This program reflects a reactive, desmoplastic tumor microenvironment (TME) enriched in cancer-associated fibroblasts (CAFs) and invasive tumor cells (aligning functionally with the high-risk CMS4 mesenchymal subtype).

---

### 2. Core Biological Programs

```
                       [PROGNOSTIC AXES IN COLORECTAL CANCER]
                                         │
                 ┌───────────────────────┴───────────────────────┐
                 ▼                                               ▼
     PROTECTIVE PROGRAM (HR < 1)                         RISK PROGRAM (HR > 1)
  (Favorable Overall Survival)                       (Unfavorable Overall Survival)
                 │                                               │
  ├── Intestinal Epithelial Lineage              ├── TGF-β/Activin & Stromal ECM
  │   (CDX2, CDX1, MYO5B, LGALS4)                │   (INHBB, ITGBL1, TPM4, ZEB1-AS1)
  └── Mitochondrial OxPhos & Metabolism          └── Immunosuppressive Microenvironment
      (NDUFA9, ATP23, ATP5G1, CS)                    (NT5E/CD73, MIR31HG, DCBLD2)
```

#### Program 1: Intestinal Epithelial Lineage Differentiation & Enterocyte Polarity
* **Direction / Prognostic Association:** Protective ($\text{HR} < 1$, Favorable OS)
* **Major Supporting Genes:** *CDX2* ($\text{HR} = 0.748$, $\text{FDR} = 0.0355$), *CDX1* ($\text{HR} = 0.781$, $\text{FDR} = 0.0573$), *MYO5B* ($\text{HR} = 0.748$, $\text{FDR} = 0.0282$), *LGALS4* ($\text{HR} = 0.771$, $\text{FDR} = 0.0512$), *MYB* ($\text{HR} = 0.771$, $\text{FDR} = 0.0192$)
* **Standardized Pathway:** GO:0030036 (Epithelial Cell Differentiation) / KEGG: hsa04520 (Adherens Junction)
* **Biological Rationale:** *CDX2* and *CDX1* are master caudal homeobox transcription factors that govern intestinal mucosal identity and suppress oncogenic dedifferentiation. *MYO5B* directs apical membrane trafficking and brush border microvillus integrity, while *LGALS4* (Galectin-4) stabilizes luminal epithelial cell-cell adhesion. Retention of this program signifies well-differentiated, less invasive tumor architecture.
* **Evidence Strength & Limitations:** Strong clinical and biological evidence. Limitation: Expression levels in bulk transcriptomics are influenced by tumor purity (ratio of epithelial tumor cells to stromal infiltrates).

#### Program 2: Mitochondrial Oxidative Phosphorylation & Metabolic Homeostasis
* **Direction / Prognostic Association:** Protective ($\text{HR} < 1$, Favorable OS)
* **Major Supporting Genes:** *NDUFA9* ($\text{HR} = 0.689$, $\text{FDR} = 0.0086$), *ATP23* ($\text{HR} = 0.688$, $\text{FDR} = 0.0066$), *ATP5G1* ($\text{HR} = 0.747$, $\text{FDR} = 0.0519$), *ATP5B* ($\text{HR} = 0.748$, $\text{FDR} = 0.0593$), *CS* ($\text{HR} = 0.754$, $\text{FDR} = 0.0388$), *OGDHL* ($\text{HR} = 0.686$, $\text{FDR} = 0.0744$), *MCCC2* ($\text{HR} = 0.739$, $\text{FDR} = 0.0282$)
* **Standardized Pathway:** KEGG: hsa00190 (Oxidative Phosphorylation) / Reactome: R-HSA-1428517 (TCA Cycle and Respiratory Electron Transport)
* **Biological Rationale:** Structural subunits of Complex I (*NDUFA9*), ATP Synthase / Complex V (*ATP5G1*, *ATP5B*), mitochondrial assembly factors (*ATP23*), and rate-limiting TCA enzymes (*CS*, *OGDHL*) are coordinately associated with longer overall survival. Downregulation of mitochondrial bioenergetics typically reflects a Warburg glycolytic shift, metabolic stress, and tumor hypoxia linked to aggressive disease progression.
* **Evidence Strength & Limitations:** High statistical consistency across multiple respiratory chain complexes. Limitation: Bulk transcriptomic expression cannot distinguish whether high OxPhos signals originate from tumor cells or infiltrating non-transformed host tissues.

#### Program 3: TGF-$\beta$/Activin Paracrine Signaling & Mesenchymal Stromal Remodeling
* **Direction / Prognostic Association:** Risk ($\text{HR} > 1$, Unfavorable OS)
* **Major Supporting Genes:** *INHBB* ($\text{HR} = 1.433$, $\text{FDR} = 0.0011$), *ITGBL1* ($\text{HR} = 1.299$, $\text{FDR} = 0.0306$), *TPM4* ($\text{HR} = 1.364$, $\text{FDR} = 0.0089$), *ZEB1-AS1* ($\text{HR} = 1.372$, $\text{FDR} = 0.0086$), *DCBLD2* ($\text{HR} = 1.408$, $\text{FDR} = 0.0086$), *ABL2* ($\text{HR} = 1.301$, $\text{FDR} = 0.0276$)
* **Standardized Pathway:** MSigDB Hallmark: Epithelial Mesenchymal Transition / KEGG: hsa04350 (TGF-beta Signaling Pathway)
* **Biological Rationale:** *INHBB* (encoding the Inhibin $\beta_B$ subunit of Activin B) and *ITGBL1* act in concert within the TME to hyperactivate TGF-$\beta$/Smad pathways, stimulating cancer-associated fibroblast (CAF) proliferation and ECM deposition. *ZEB1-AS1* epigenetically reinforces ZEB1-driven transcriptomic repression of epithelial markers. Cytoskeletal factors (*TPM4*, *ABL2*) mediate focal adhesion assembly and actin contractility necessary for cell invasion.
* **Evidence Strength & Limitations:** Highly significant effect sizes (*INHBB* is the top risk gene in the dataset). Limitation: Strong alignment with CAF abundance; cannot definitively establish whether *INHBB* acts cell-autonomously or via paracrine microenvironmental stroma.

#### Program 4: Ecto-Nucleotidase Adenosinergic Activity & Tumor Microenvironmental Immunosuppression
* **Direction / Prognostic Association:** Risk ($\text{HR} > 1$, Unfavorable OS)
* **Major Supporting Genes:** *NT5E* ($\text{HR} = 1.313$, $\text{FDR} = 0.0394$), *MIR31HG* ($\text{HR} = 1.309$, $\text{FDR} = 0.0066$), *PTPN14* ($\text{HR} = 1.362$, $\text{FDR} = 0.0250$), *AKT3* ($\text{HR} = 1.318$, $\text{FDR} = 0.0388$)
* **Standardized Pathway:** Reactome: R-HSA-9694516 (Nucleotide Metabolism in Immune Suppression) / KEGG: hsa04151 (PI3K-Akt Signaling Pathway)
* **Biological Rationale:** *NT5E* (CD73) catalyzes the conversion of extracellular AMP to adenosine, a potent immunosuppressive metabolite that inhibits cytotoxic T-cell and NK-cell anti-tumor activity. *MIR31HG* promotes inflammatory/senescent secretory phenotypes and therapy resistance. In parallel, reduced expression of antigen presentation machinery (*TAPBPL*, $\text{HR} = 0.711$, $\text{FDR} = 0.0192$) in high-risk tumors indicates immune evasion.
* **Evidence Strength & Limitations:** Supported by established biochemical pathways of tumor immunotolerance. Limitation: Functional validation requires direct single-cell resolution of infiltrating immune cell populations.

---

### 3. Key Genes and Interaction Modules

| Candidate Gene(s) | Dataset HR & FDR | Functional Role in Core Programs | Proposed Relationship & Relationship Nature |
| :--- | :--- | :--- | :--- |
| **CDX2 & CDX1** | *CDX2*: $\text{HR}=0.748$, $\text{FDR}=0.0355$<br>*CDX1*: $\text{HR}=0.781$, $\text{FDR}=0.0573$ | Lineage-defining transcription factors regulating intestinal epithelial differentiation. | **Regulatory Interaction & Pathway Co-membership**: Paralogy-related transcription factors that co-occupy promoter regions of enterocyte-specific genes (*MYO5B*, *LGALS4*). |
| **INHBB & ITGBL1** | *INHBB*: $\text{HR}=1.433$, $\text{FDR}=0.0011$<br>*ITGBL1*: $\text{HR}=1.299$, $\text{FDR}=0.0306$ | Secreted stromal drivers of TGF-$\beta$ signaling, CAF activation, and ECM fibrosis. | **Pathway Co-membership & Co-expression**: Both are upregulated in reactive tumor stroma (CMS4 subtype) and co-stimulate pro-invasive signaling cascades. |
| **ATP5G1 & ATP5B** | *ATP5G1*: $\text{HR}=0.747$, $\text{FDR}=0.0519$<br>*ATP5B*: $\text{HR}=0.748$, $\text{FDR}=0.0593$ | Core catalytic ($F_1$) and rotor ($F_0$) subunits of mitochondrial ATP Synthase (Complex V). | **Direct Physical Interaction**: Physical assembly into the multi-protein ATP synthase complex within the inner mitochondrial membrane. |
| **ZEB1-AS1 & MIR31HG** | *ZEB1-AS1*: $\text{HR}=1.372$, $\text{FDR}=0.0086$<br>*MIR31HG*: $\text{HR}=1.309$, $\text{FDR}=0.0066$ | Long non-coding RNAs promoting EMT, epigenetic repression of epithelial genes, and invasive phenotypes. | **Co-expression & Functional Convergence**: Independent lncRNA loci showing co-expression in mesenchymal-like CRC, jointly driving epigenetic EMT programs. |
| **MYO5B & LGALS4** | *MYO5B*: $\text{HR}=0.748$, $\text{FDR}=0.0282$<br>*LGALS4*: $\text{HR}=0.771$, $\text{FDR}=0.0512$ | Markers of apical brush-border transport and intestinal mucosal cell-cell adhesion. | **Pathway Co-membership**: Shared downstream membership in the differentiated enterocyte structural program without direct physical complex formation. |
| **DCBLD2 & ABL2** | *DCBLD2*: $\text{HR}=1.408$, $\text{FDR}=0.0086$<br>*ABL2*: $\text{HR}=1.301$, $\text{FDR}=0.0276$ | Transmembrane receptor auxiliary factor (*DCBLD2*) and non-receptor tyrosine kinase (*ABL2*) driving invasion. | **Indirect Signaling Cross-talk**: *DCBLD2* promotes RTK endocytosis/signaling, which signals downstream to *ABL2* to induce actin cytoskeletal dynamics and cell motility. |
| **NT5E (CD73)** | *NT5E*: $\text{HR}=1.313$, $\text{FDR}=0.0394$ | Ecto-5'-nucleotidase generating adenosine to impair anti-tumor immune responses. | **Co-expression / Functional Interaction**: Co-expressed with CAF/stromal markers (*INHBB*, *ITGBL1*) to establish an immunosuppressive TME niche. |
| **NDUFA9** | *NDUFA9*: $\text{HR}=0.689$, $\text{FDR}=0.0086$ | Core subunit of mitochondrial Complex I involved in electron transport and NADH oxidation. | **Pathway Co-membership**: Functions upstream of Complex V (*ATP5G1*, *ATP5B*) in the oxidative phosphorylation supercomplex. |
| **TAPBPL** | *TAPBPL*: $\text{HR}=0.711$, $\text{FDR}=0.0192$ | TAP-binding protein-like chaperone facilitating MHC Class I peptide loading. | **Pathway Co-membership**: Participates in the antigen processing and presentation pathway required for CD8+ T-cell recognition. |
| **TPM4** | *TPM4*: $\text{HR}=1.364$, $\text{FDR}=0.0089$ | Tropomyosin isoform stabilizing actin filaments in migratory tumor cells and myofibroblasts. | **Direct Physical Interaction (with Actin)**: Binds directly along actin microfilaments to regulate non-muscle cell contractility and stress fiber formation. |

---

### 4. Validation Priorities

```
[INPUT DATASET: HR & FDR]
  ├── INHBB (HR=1.43, FDR=0.0011) ──────► Priority 3: Therapeutic Target (INHBB/TGF-β Axis)
  ├── CDX2 / MYO5B vs INHBB Ratio ──────► Priority 2: Biomarker Signature Validation
  ├── Bulk Stromal vs Epithelial Signals ─► Priority 1: Confounding Composition Check (Single-Cell/Spatial)
  ├── NDUFA9 / ATP5B (HR~0.69-0.75) ─────► Priority 4: Mechanistic Hypothesis (OxPhos Metabolic Shift)
  └── NT5E / CD73 (HR=1.31, FDR=0.039) ──► Priority 5: Interaction Hypothesis (Adenosinergic Immunosuppression)
```

#### Priority 1: Single-Cell & Spatial Deconvolution of Tumor vs. Stromal Transcriptomic Signals
* **Category:** Confounding or composition check
* **Prioritization Rationale:** Bulk tissue expression of high-risk genes (*INHBB*, *ITGBL1*, *TPM4*, *NT5E*) may reflect high cancer-associated fibroblast (CAF) density rather than cell-intrinsic oncogenic changes within tumor enterocytes.
* **Dataset Evidence:** Inverse prognostic correlation between epithelial enterocyte genes ($\text{HR} < 1$) and mesenchymal/stromal genes ($\text{HR} > 1$).
* **External Evidence:** Colorectal Cancer Consensus Molecular Subtypes (CMS1–4) demonstrate that CMS4 (stromal-rich) carries worse overall survival, driven largely by TME composition.
* **Next Steps:** Perform single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics on primary CRC tissue sections to resolve cell-type-specific expression profiles.
* **Conclusion Level:** **Supported hypothesis**

#### Priority 2: Validation of a Composite Epithelial-to-Mesenchymal Gene Ratio Biomarker
* **Category:** Biomarker
* **Prioritization Rationale:** Single-gene biomarkers often lack sufficient prognostic sensitivity. A dual-axis composite score (e.g., $[CDX2 + MYO5B] / [INHBB + ITGBL1]$) leverages opposing biological programs for enhanced survival stratification.
* **Dataset Evidence:** *INHBB* ($\text{HR} = 1.433$, $\text{FDR} = 0.0011$) and *CDX2* ($\text{HR} = 0.748$, $\text{FDR} = 0.0355$) show strong, opposing association signals.
* **External Evidence:** Loss of CDX2 protein expression by immunohistochemistry (IHC) is an established adverse prognostic marker in Stage II/III CRC; combining CDX2 with stromal TGF-$\beta$ markers improves predictive accuracy.
* **Next Steps:** Develop an RT-qPCR / NanoString panel and evaluate the prognostic ratio in independent, fully annotated clinical cohorts (e.g., TCGA-COAD, GSE39582) using multivariate Cox models adjusted for TNM stage and MMR status.
* **Conclusion Level:** **Established evidence** (for CDX2 baseline prognostic utility); **Supported hypothesis** (for the composite stromal-epithelial gene ratio).

#### Priority 3: Functional Disruption of the INHBB / Activin B Signaling Axis in Invasive CRC
* **Category:** Therapeutic target
* **Prioritization Rationale:** *INHBB* exhibits the largest hazard ratio ($\text{HR} = 1.433$, $P = 2.00 \times 10^{-8}$) in the dataset, identifying it as a promising candidate for targeted intervention in aggressive CRC.
* **Dataset Evidence:** *INHBB* leads the risk-associated gene set with strong statistical significance.
* **External Evidence:** Activin B (homodimer of INHBB subunits) activates ALK4/7 receptors to promote SMAD2/3 phosphorylation, driving EMT, stemness, and therapy resistance in Gastrointestinal cancers.
* **Next Steps:** Evaluate the effect of *INHBB* shRNA knockdown or neutralizing antibodies on cell invasion, CAF activation, and chemoresistance in 3D patient-derived organoid-CAF co-culture systems.
* **Conclusion Level:** **Exploratory hypothesis**

#### Priority 4: Functional Characterization of Mitochondrial OxPhos Suppression in CRC Progression
* **Category:** Mechanistic hypothesis
* **Prioritization Rationale:** Coordinated downregulation of multiple inner mitochondrial membrane subunits (*NDUFA9*, *ATP5G1*, *ATP5B*, *TIMM13*) correlates with poor survival, suggesting that mitochondrial bioenergetic impairment facilitates metastasis.
* **Dataset Evidence:** Consistent $\text{HR} < 1$ values ($\text{HR} \approx 0.68 - 0.75$, $\text{FDR} < 0.06$) across independent mitochondrial respiratory chain complexes.
* **External Evidence:** Loss of mitochondrial Complex I or metabolic reprogramming towards uncoupled glycolysis enhances invasive behavior and ROS-mediated signaling in colorectal cancer cells.
* **Next Steps:** Perform Seahorse extracellular flux analysis (OCR vs. ECAR) on CRC organoid lines with differential expression of *NDUFA9* and *ATP5B* to evaluate metabolic flexibility and metastatic potential.
* **Conclusion Level:** **Supported hypothesis**

#### Priority 5: Microenvironmental Targeting of NT5E (CD73)-Mediated Immunosuppression
* **Category:** Interaction / network hypothesis
* **Prioritization Rationale:** High *NT5E* expression ($\text{HR} = 1.313$, $\text{FDR} = 0.0394$) combined with low *TAPBPL* ($\text{HR} = 0.711$) suggests an immune-excluded microenvironment characterized by high extracellular adenosine and deficient antigen presentation.
* **Dataset Evidence:** Significant association of *NT5E* with poor overall survival in colorectal tissue samples.
* **External Evidence:** Monoclonal antibodies targeting CD73 (e.g., oleclumab) are currently under clinical investigation to reverse adenosine-mediated T-cell suppression and restore immune surveillance.
* **Next Steps:** Conduct flow cytometry and multiplex immunofluorescence on primary CRC resections to correlate CD73 expression on tumor/stromal cells with CD8+ T-cell infiltration and exhaustion markers (PD-1, TIM-3).
* **Conclusion Level:** **Exploratory hypothesis**

---

### 5. Evidence Grounding

```
                     ┌─────────────────────────────────────────┐
                     │          EVIDENCE SOURCES               │
                     └────────────────────┬────────────────────┘
                                          │
    ┌────────────────┬────────────────────┼────────────────────┬────────────────┐
    ▼                ▼                    ▼                    ▼                ▼
[Dataset Direct] [Pathway/Ontology]   [Protein/PPI]     [Disease/CMS]    [Therapeutic]
- INHBB HR=1.43  - GO: OxPhos         - ATP5G1-ATP5B    - CMS4 Stromal   - CD73 Inhibitors
- CDX2 HR=0.75   - Reactome: EMT        Complex V          Subtype Pheno   - TGF-β Blockade
- FDR < 0.05     - KEGG: Cytokines    - CDX1/2 Reg Net   - Stage II/III   - Anti-PD-1
```

* **Direct Dataset Evidence:** Derived from survival statistics provided in the input table. High-confidence signals include *INHBB* ($\text{HR} = 1.433$, $\text{FDR} = 0.0011$), *SCARA3* ($\text{HR} = 1.377$, $\text{FDR} = 0.0024$), *ATP23* ($\text{HR} = 0.688$, $\text{FDR} = 0.0066$), *DCBLD2* ($\text{HR} = 1.408$, $\text{FDR} = 0.0086$), *NDUFA9* ($\text{HR} = 0.689$, $\text{FDR} = 0.0086$), and *CDX2* ($\text{HR} = 0.748$, $\text{FDR} = 0.0355$).
* **Pathway & Ontology Evidence:** Standardized annotation links *NDUFA9*, *ATP5G1*, *ATP5B*, and *CS* to KEGG hsa00190 (Oxidative Phosphorylation), while *INHBB*, *ITGBL1*, *TPM4*, and *ZEB1-AS1* map to MSigDB Hallmark Epithelial-Mesenchymal Transition.
* **Protein Interaction & Regulatory Evidence:** Structural databases validate that *ATP5G1* and *ATP5B* physically interact within the ATP synthase complex. Transcriptional literature confirms regulatory cross-talk where *CDX2* and *CDX1* directly bind promoter regions of intestinal brush-border genes (*MYO5B*).
* **Disease & Clinical Subtype Association:** The transcriptomic pattern strongly mirrors the consensus molecular subtyping (CMS) framework of CRC, where CMS2/CMS3 (canonical/metabolic, high CDX2/OxPhos) carries favorable outcomes relative to CMS4 (mesenchymal, high INHBB/ITGBL1/TGF-$\beta$).
* **Therapeutic Evidence:** *NT5E* (CD73) represents a druggable enzyme with active targeted clinical trials. However, therapeutic targeted status alone does not prove efficacy in this unselected CRC cohort.
* **Evidence Synthesis & Conflict Resolution:** Dataset results demonstrate internal consistency between epithelial marker downregulation and stromal/EMT marker upregulation. Apparent conflicts (e.g., simultaneous protective association of mucosal chemokines like *CCL15* vs. risk association of *NT5E*) reflect distinct sub-regional immunological states (e.g., mucosal intraepithelial surveillance vs. stromal immunosuppression).

---

### 6. Limitations and Alternative Explanations

1. **Tumor Purity and Cell Composition Confounding:**
   * *Issue:* Microarray/RNA-seq signals from bulk tissue homogenates blend tumor cells, cancer-associated fibroblasts, endothelial cells, and immune infiltrates. High expression of risk genes (*INHBB*, *ITGBL1*, *TPM4*) may reflect high CAF density rather than increased intrinsic aggressiveness of tumor enterocytes.
   * *Investigation:* Apply computational cell-type deconvolution algorithms (e.g., CIBERSORTx, EPIC) or validate via single-cell/spatial RNA sequencing.

2. **Unadjusted Clinical Covariates (TNM Stage, MMR Status, BRAF Mutations):**
   * *Issue:* Hazard ratios derived from univariate survival analyses may be confounded by clinical parameters. For example, loss of *CDX2* or elevated *NT5E* may correlate with advanced TNM stage (Stage IV) or Microsatellite Instability (MSI-H / dMMR) status.
   * *Investigation:* Perform multivariate Cox proportional hazards modeling adjusting for clinical stage, age, sex, anatomic site (right vs. left colon), and MMR/BRAF mutation status.

3. **Array Probe Annotation Artifacts and Uncharacterized Loci:**
   * *Issue:* The input features contain unannotated microarray probes (e.g., `PROBE_237290_at`, `PROBE_233690_at`) and complex RNA clusters (e.g., `MIR1248|SNORA81...`). Hybridization cross-reactivity or outdated gene models could skew individual locus statistics.
   * *Investigation:* Re-map probe target sequences to the current GRCh38 human genome reference and validate transcripts using RNA-seq or quantitative RT-qPCR.

4. **Broad Pathway Enrichment vs. Specific Functional Drivers:**
   * *Issue:* The protective signal of mitochondrial genes (*ATP5G1*, *ATP5B*, *NDUFA9*, *CS*) could reflect overall cell viability, cellular differentiation state, or mitochondrial mass rather than specific reliance on oxidative phosphorylation.
   * *Investigation:* Assess functional mitochondrial respiratory capacity and metabolite fluxes in primary CRC organoid lines across differentiation gradients.

5. **Association vs. Causation Ambiguity in Dedifferentiation:**
   * *Issue:* Downregulation of lineage markers (*CDX2*, *CDX1*, *MYO5B*) may be a passive downstream consequence of aggressive tumor dedifferentiation and genomic instability rather than an active driver of tumor progression.
   * *Investigation:* Conduct CRISPR-mediated gene knockout and overexpression experiments in non-invasive vs. invasive CRC models to establish functional necessity in driving metastatic potential.
